Center for Disease Dynamics, Economics & Policy

About: Center for Disease Dynamics, Economics & Policy is a nonprofit organization based out in Washington D.C., District of Columbia, United States. It is known for research contribution in the topics: Population & Antibiotic resistance. The organization has 76 authors who have published 320 publications receiving 21403 citations.

Reply to Charra et al.: Global longitudinal assessment of 2019 changes in defined daily doses.

Abstract: The concept of defined daily doses (DDDs) is rooted in the understanding that to assess drug utilization and to develop rational interventions at the patient level, a common framework for comparing varied sources and forms of drug utilization data are necessary (1⇓–3). A primary aim of the WHO Collaborating Centre for Drug Statistics Methodology (WHO-CC-DSM), which maintains DDD values, is to keep DDD values as stable as possible for the purposes of evaluating longitudinal drug utilization data. Because the DDDs for antibiotics have been a matter of debate for many years, the WHO-CC-DSM decided to implement DDD changes for several Anatomical Therapeutic Chemical (ATC) classification codes [ATC/DDD Index; e.g., amoxicillin (J01CA04) and amoxicillin/clavulanic acid (J01CR02)] starting January 1, … [↵][1]1To whom correspondence should be addressed. Email: klein{at}cddep.org. [1]: #xref-corresp-1-1

Reply to Abat et al.: Improved policies necessary to ensure an effective future for antibiotics

Abstract: Antibiotics, particularly penicillins, have been instrumental in lowering mortality associated with pneumococcal pneumonia since they were introduced in the 1950s (1). As we recently reported (2), since 2000, global antibiotic use has increased significantly, driven largely by increases in low- and middle-income countries (LMICs). Given this association, we read with interest the letter from Abat et al. (3), based on data from the Global Burden of Disease Study (4, 5), that noted a correlation between the increase in antibiotic use we reported and reductions in mortality from lower respiratory tract infections (LRTIs), particularly due to streptococcal and Haemophilus influenza type B infections. However, while these diseases remain treatable by first-line antibiotics in many parts of the world, there are two reasons why the cause of the decrease in mortality may not be due to increases in … [↵][1]1To whom correspondence should be addressed. Email: klein{at}cddep.org. [1]: #xref-corresp-1-1

Trends in antibiotic resistance among bacteria isolated from blood cultures using a large private laboratory network data in India: 2008-2014

Abstract: Antimicrobial resistance surveillance is essential to track changes in microbial populations, estimate the magnitude of the problem and to design and evaluate interventions. However, there is no national level information on resistance among bacteria causing bloodstream infections in India.